MBX Biosciences Inc. Common Stock (MBX)
Stock · NASDAQ · Health Care
$49.66as of 10/16/2026
Price chart
Active signals
MBX Signal Track Record
How signals performed across all stocks →What MBX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 10 | +7.8% | 50% | September 16, 2026 |
| Bollinger Band Breakout | 10 | -0.9% | 40% | July 30, 2026 |
| Bollinger Band Breakdown | 4 | +0.5% | 50% | September 24, 2026 |
| Any 20-session window (baseline) | +8.6% | 62% |
Computed by MarketWall from daily closing prices since July 2, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 63
- Website
- mbxbio.com/
Fundamentals
- 1-day range
- $48.73$51.17
- Market cap
- $3.19B
- P/E (trailing)
- —
- P/E (forward)
- -12.75
- EPS (trailing)
- $-2.41
- Dividend yield
- —
- Beta
- 1.65
- Avg. volume
- 523.8K
Forecasts
10 analyst ratings
MBX Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
- IRONDisc Medicine Inc. Common Stock$56.84▲ 0.34%Market cap $2.97BP/E —$40$99.5
- IMNMImmunome Inc. Common Stock$16.47▼ 5.34%Market cap $2.92BP/E —$13.54$30.06
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
| IRON Disc Medicine Inc. Common Stock | $2.97B | — | $56.84 | ▲ 0.34% | $40$99.5 |
| IMNM Immunome Inc. Common Stock | $2.92B | — | $16.47 | ▼ 5.34% | $13.54$30.06 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84benzinga · 10/12/2026
- Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?Yahoo · 10/10/2026
- MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%Yahoo · 10/10/2026
- Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150Benzinga · 10/2/2026
- Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On MondayBenzinga · 9/28/2026
- MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)SeekingAlpha · 9/23/2026
- MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Azoulay Salomon · August 4, 2026 · Sale370 @ $65.77
- John W. Smither · August 3, 2026 · Grant28.0K
- Hoerter Steven L. · August 3, 2026 · Grant331.0K
- Hoerter Steven L. · August 3, 2026 · Grant71.0K
- John W. Smither · August 3, 2026 · Grant130.0K
- Stelzer Laurie · June 4, 2026 · Grant12.5K
- Hoerter Steven L. · June 4, 2026 · Grant12.5K
- Pescovitz Ora H. · June 4, 2026 · Grant12.5K
- Patrick J. Heron · June 4, 2026 · Grant12.5K
- Edward T. Mathers · June 4, 2026 · Grant12.5K
- Ryder Steven · June 4, 2026 · Grant12.5K
- Aynechi Tiba · June 4, 2026 · Grant12.5K
- Azoulay Salomon · May 8, 2026 · Option Exercise15.0K @ $16
- Azoulay Salomon · May 8, 2026 · Option Exercise55.0K @ $10.46
- Azoulay Salomon · May 8, 2026 · Sale15.0K @ $38.3
Institutional Ownership
March 31, 2026
- Total shares held
- 52.03M
- Total value held
- $1.52B
- Institutional holders
- 151
- Unknown6.65M
- Unknown3.64M
- Unknown3.61M
- Unknown3.19M
- Unknown2.94M
- Unknown2.94M
- Unknown2.76M
- Unknown2.14M
- Unknown1.62M
- Unknown1.49M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised
MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.